BACKGROUND: Although the presence of an RV lead is a potential cause of tricuspid regurgitation (TR), the clinical impact of significant lead-induced TR is unknown. OBJECTIVE: To evaluate the effect of significant lead-induced TR on cardiac performance and long-term outcome after cardioverter-defibrillator (ICD) or pacemaker implantation. METHODS: A retrospective cohort of 239 ICD (n=191) or pacemaker (n=48) recipients (age 60±14 years, 77% male) from a tertiary care university hospital, with an echocardiographic evaluation before and within 1-1.5 years after device implantation were included. Significant lead-induced TR was defined as TR worsening, reaching a grade ≥2 at follow-up echocardiography. During long-term follow-up (median 58, IQR 35-76 months), all-cause mortality and heart failure related events were recorded. RESULTS: Before device implantation, most patients had TR grade 1 or 2 (64.0%) or no TR (33.9%), but after lead placement, significant TR was seen in 91 patients (38%). Changes in cardiac volumes and function at follow-up were similar between patients with and without significant lead-induced TR, except for larger RV diastolic area (17±6mm(2) vs 16±5mm(2), p=0.009), larger right atrial diameter (39±10 mm vs 36±8 mm, p<0.001) and higher pulmonary arterial pressures (41±15 mm Hg vs 33±10 mm Hg, p<0.001) in patients with significant lead-induced TR. Patients with significant lead-induced TR had worse long-term survival (HR=1.687, p=0.040) and/or more heart failure related events (HR=1.641, p=0.019). At multivariate analysis, significant lead-induced TR was independently associated with all-cause mortality (HR=1.749, p=0.047) together with age, LVEF and percentage RV pacing. CONCLUSIONS: Significant lead-induced TR is associated with poor long-term prognosis. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
BACKGROUND: Although the presence of an RV lead is a potential cause of tricuspid regurgitation (TR), the clinical impact of significant lead-induced TR is unknown. OBJECTIVE: To evaluate the effect of significant lead-induced TR on cardiac performance and long-term outcome after cardioverter-defibrillator (ICD) or pacemaker implantation. METHODS: A retrospective cohort of 239 ICD (n=191) or pacemaker (n=48) recipients (age 60±14 years, 77% male) from a tertiary care university hospital, with an echocardiographic evaluation before and within 1-1.5 years after device implantation were included. Significant lead-induced TR was defined as TR worsening, reaching a grade ≥2 at follow-up echocardiography. During long-term follow-up (median 58, IQR 35-76 months), all-cause mortality and heart failure related events were recorded. RESULTS: Before device implantation, most patients had TR grade 1 or 2 (64.0%) or no TR (33.9%), but after lead placement, significant TR was seen in 91 patients (38%). Changes in cardiac volumes and function at follow-up were similar between patients with and without significant lead-induced TR, except for larger RV diastolic area (17±6mm(2) vs 16±5mm(2), p=0.009), larger right atrial diameter (39±10 mm vs 36±8 mm, p<0.001) and higher pulmonary arterial pressures (41±15 mm Hg vs 33±10 mm Hg, p<0.001) in patients with significant lead-induced TR. Patients with significant lead-induced TR had worse long-term survival (HR=1.687, p=0.040) and/or more heart failure related events (HR=1.641, p=0.019). At multivariate analysis, significant lead-induced TR was independently associated with all-cause mortality (HR=1.749, p=0.047) together with age, LVEF and percentage RV pacing. CONCLUSIONS: Significant lead-induced TR is associated with poor long-term prognosis. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Entities:
Keywords:
HEART FAILURE; QUALITY OF CARE AND OUTCOMES
Authors: Ulas Höke; Mand J H Khidir; Enno T van der Velde; Martin J Schalij; Jeroen J Bax; Victoria Delgado; Nina Ajmone Marsan Journal: Clin J Am Soc Nephrol Date: 2015-09-25 Impact factor: 8.237
Authors: Katarzyna Wiechecka; Bartosz Wiechecki; Agnieszka Kapłon-Cieślicka; Agata Tymińska; Monika Budnik; Dominika Hołowaty; Krzysztof Jakubowski; Marcin Michalak; Elżbieta Świętoń; Przemysław Stolarz; Roman Steckiewicz; Marcin Grabowski; Piotr Scisło; Janusz Kochanowski; Krzysztof J Filipiak; Grzegorz Opolski Journal: Cardiol J Date: 2019-06-21 Impact factor: 2.737
Authors: Daniel P Rothschild; James A Goldstein; Nathan Kerner; Amr E Abbas; Meet Patel; Wai Shun Wong Journal: J Interv Card Electrophysiol Date: 2017-07-06 Impact factor: 1.900
Authors: Francesca N Delling; Zena K Hassan; Gail Piatkowski; Connie W Tsao; Alefiyah Rajabali; Lawrence J Markson; Peter J Zimetbaum; Warren J Manning; James D Chang; Kenneth J Mukamal Journal: Am J Cardiol Date: 2016-01-06 Impact factor: 2.778
Authors: Dorota Nowosielecka; Wojciech Jacheć; Anna Polewczyk; Andrzej Kleinrok; Łukasz Tułecki; Andrzej Kutarski Journal: Cardiovasc Diagn Ther Date: 2021-04
Authors: Martin Riesenhuber; Andreas Spannbauer; Marianne Gwechenberger; Thomas Pezawas; Christoph Schukro; Günter Stix; Matthias Schneider; Georg Goliasch; Anahit Anvari; Thomas Wrba; Cesar Khazen; Martin Andreas; Günther Laufer; Christian Hengstenberg; Mariann Gyongyosi Journal: Clin Res Cardiol Date: 2021-02-10 Impact factor: 5.460